• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

September 2, 2019
Company Drug/Device Medical Condition Status
CStone Pharmaceuticals avapritinib GIST Phase 1 trial initiated
CStone Pharmaceuticals CS3002 advanced solid tumors Phase 1 trial initiated enrolling subjects in Australia
Alkahest GRF6021 Primary hip or knee arthroplasty Phase 2 trial initiated enrolling 45 subjects
Mag Force AG NanoTherm therapy Cancer lesions for prostate cancer Phase 2 trial initiated enrolling 120 male subjects at the Texas Urology Group, the University of Texas, San Antonio and the University of Washington, Seattle
Aimmune Therapeutics, Inc. AR201 egg allergy Phase 2 trial initiated enrolling 84 children, adolescents and young adults ages 4 to 26 years of age with hen egg allergy at 15 sites in the U.S.
Fulcrum Therapeutics Losmapimod (selective p38alpha/beta MAPK inhibitor) facioscapulohumeral muscular dystrophy (FSHD) Phase 2b trial initiated enrolling subjects with genetically confirmed FSHD
Mitsubishi Tanabe Pharma Corporation ND0612 Parkinson's disease with motor fluctuations Phase 3 trial initiated enrolling 300 subjects with PD experiencing motor fluctuations, whose symptoms are no longer controlled by conventional treatments at approximately 120 sites globally
VenatoRx Pharmaceuticals cefepime/VNRX-5133 complicated urinary tract infection (cUTI) Phase 3 trial initiated enrolling 582 adult subjects with cUTI, including acute pyelonephritis
DiscGenics, Inc. IDCT degenerative disc disease (DDD) Fast Track designation granted by the FDA
CrystalGenomics, Inc. CG-745 pancreatic cancer Orphan Drug Designation granted by the FDA
Kyowa Kirin Co., Ltd. NOURIANZ (istradefylline) Parkinson’s disease Approval granted by the FDA
Eli Lilly and Company Taltz (ixekizumab) injection 80 mg/mL active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA) Approval granted by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing